What question did this study set out to answer?

To analyze the impact of novel therapies on causes of death in chronic lymphocytic leukemia patients.

December 8, 2025BloodOpen Access

Causes of death in chronic lymphocytic leukemia/small lymphocytic lymphoma during the novel agent era: A population-based analysis

View Full Paper

Ask AI

Bookmark

Authors

Population-based analysis shows improved survival and reduced mortality from CLL with novel therapies, suggesting a need for continued research.

To analyze the impact of novel therapies on causes of death in chronic lymphocytic leukemia patients.
Utilized the SEER database for a population-based analysis of CLL patients from 2008 to 2019.
Compared overall survival and causes of death between pre-novel agent and novel agent eras.
Employed Kaplan-Meier survival estimates and Cox regression for multivariable analysis.
Included 9913 patients in the analysis, with a median follow-up of 7.8 years.
5-year overall survival was significantly higher in the novel agent cohort (65.3%) compared to pre-novel agent (61.0%).
Patients receiving novel therapies showed a lower risk of death from CLL and other cancers, but a nonsignificant trend towards higher mortality risk from cardiovascular diseases.

Voutsinas et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Population-based analysis shows improved survival and reduced mortality from CLL with novel therapies, suggesting a need for continued research.